Cargando…

A T2* MRI prospective survey on heart iron in thalassemia major patients treated with sequential deferiprone-desferrioxamine versus deferipron and desferrioxamine in monotherapy

Detalles Bibliográficos
Autores principales:	Pepe, Alessia, Meloni, Antonella, Rossi, Giuseppe, Dell'Amico, Maria Chiara, Prossomariti, Luciano, D'Ascola, Domenico G, Filosa, Aldo, Pepe, Pasquale, Positano, Vincenzo, Ascioti, Claudio, Capra, Marcello, Lombardi, Massimo
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3106517/ http://dx.doi.org/10.1186/1532-429X-13-S1-P304

Ejemplares similares

Prospective comparison on cardiac iron by MR in thalassemia major patients treated with combination deferipron-desferrioxamine versus deferipron and desferrioxamine in monoterapy
por: Pepe, Alessia, et al.
Publicado: (2011)

A T2* MRI prospective survey on heart iron in thalassemia major patients treated with sequential deferipron-desferrioxamine versus deferasirox
por: Pepe, Alessia, et al.
Publicado: (2011)

A T2* MRI prospective survey on heart iron in thalassemia major patients treated with deferasirox versus deferiprone and desferrioxamine in monotherapy
por: Pepe, Alessia, et al.
Publicado: (2011)

MRI prospective survey on cardiac and hepatic iron in transfusion-dependent thalassemia intermedia patients treated with desferrioxamine, deferiprone and deferasirox
por: Meloni, Antonella, et al.
Publicado: (2015)

Cardiac and hepatic iron and ejection fraction in thalassemia major: Multicentre prospective comparison of combined Deferiprone and Deferoxamine therapy against Deferiprone or Deferoxamine Monotherapy
por: Pepe, Alessia, et al.
Publicado: (2013)

Estimates of the effect on hepatic iron of oral deferiprone compared with subcutaneous desferrioxamine for treatment of iron overload in thalassemia major: a systematic review
por: Caro, J Jaime, et al.
Publicado: (2002)

A prospective MRI study of left ventricular iron and function in non-trasfusion-dependent thalassemia intermedia patients treated with desferrioxamine
por: Meloni, Antonella, et al.
Publicado: (2015)

Myocardial iron overload in sickle/thalassemia patients of Italian origin
por: Meloni, Antonella, et al.
Publicado: (2013)

Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective
por: Galanello, Renzo
Publicado: (2007)

Deferiprone-induced arthropathy in thalassemia: MRI findings in a case
por: Chand, Gyan, et al.
Publicado: (2009)

Treating thalassemia major-related iron overload: the role of deferiprone
por: Berdoukas, Vasilios, et al.
Publicado: (2012)

Desferrioxamine Reduces Oxidative Stress in the Lung Contusion
por: Basaran, Umit Nusret, et al.
Publicado: (2013)

An international survey of patients with thalassemia major and their views about sustaining life-long desferrioxamine use
por: Ward, Alexandra, et al.
Publicado: (2002)

Salmonella Typhimurium and Pseudomonas aeruginosa Respond Differently to the Fe Chelator Deferiprone and to Some Novel Deferiprone Derivatives
por: Ammendola, Serena, et al.
Publicado: (2021)

Desferrioxamine decreases NAD redox potential of intact red blood cells: evidence for desferrioxamine as an inducer of oxidant stress in red blood cells
por: Niihara, Yutaka, et al.
Publicado: (2002)

Desferrioxamine-related ocular toxicity: A case report
por: Simon, Sumu, et al.
Publicado: (2012)

Tales of the Unexpected: The Case of Zirconium(IV) Complexes with Desferrioxamine
por: Savastano, Matteo, et al.
Publicado: (2019)

T2* heterogeneity detected by CMR could be related to myocardial iron distribution in Thalassemia patients
por: Positano, Vincenzo, et al.
Publicado: (2009)

Right Ventricular Volumes and Function normalized to body surface area, age and sex in a large cohort of well-treated Thalassemia Major without myocardial iron overload
por: Meloni, Antonella, et al.
Publicado: (2011)

Contrast Sensitivity in Patients with Beta-Thalassemia Major and Sickle Cell Disease Under Regular Transfusions and Treatment with Desferrioxamine
por: Gorezis, Spyridon, et al.
Publicado: (2010)

Comparison of desferrioxamine and NODAGA for the gallium-68 labeling of exendin-4
por: Kaeppeli, Simon A. M., et al.
Publicado: (2019)

(68)Ga-labelled desferrioxamine-B for bacterial infection imaging
por: Petrik, Milos, et al.
Publicado: (2020)

Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload
por: Smith, Gillian C, et al.
Publicado: (2011)

Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone
por: Porter, John B, et al.
Publicado: (2013)

CMR survey in Thalassemia Intermedia patients
por: Meloni, Antonella, et al.
Publicado: (2014)

Right ventricular wall motion abnormalities n Thalassemia Major patients
por: Meloni, Antonella, et al.
Publicado: (2014)

Different patterns of myocardial iron overload by multislice T2* Cardiovascular MR as markers of risk for cardiac dysfunction in thalassemia major
por: Meloni, Antonella, et al.
Publicado: (2011)

S123: SAFETY AND EFFICACY OF EARLY-START DEFERIPRONE IN INFANTS AND YOUNG CHILDREN WITH BETA-THALASSEMIA (START STUDY)
por: Elalfy, M, et al.
Publicado: (2022)

Heart T2* for prediction of cardiac complications in well-treated thalassemia major patients
por: Pepe, Alessia, et al.
Publicado: (2012)

Increase of reactive oxygen species by desferrioxamine during experimental Chagas' disease
por: Francisco, Amanda Fortes, et al.
Publicado: (2013)

Phosphorylation of SMC1 by ATR is required for desferrioxamine (DFO)-induced apoptosis
por: So, E Y, et al.
Publicado: (2011)

Pulmonary effects of desferrioxamine in the treatment of an experimental model of fulminant hepatic failure
por: Kalimeris, K, et al.
Publicado: (2007)

Mitochondria-penetrating peptides conjugated to desferrioxamine as chelators for mitochondrial labile iron
por: Alta, Roxana Y. P., et al.
Publicado: (2017)

Synergistic protection of bone vasculature and bone mass by desferrioxamine in osteoporotic mice
por: Wang, Liang, et al.
Publicado: (2017)

Deferiprone targets aconitase: Implication for Friedreich's ataxia treatment
por: Goncalves, Sergio, et al.
Publicado: (2008)

Quantum chemical analysis of the deferiprone–iron binding reaction
por: Wiwanitkit, Viroj
Publicado: (2006)

Effect of Iron-Chelator Deferiprone on the In Vitro Growth of Staphylococci
por: Kim, Choon-Mee, et al.
Publicado: (2009)

Deferiprone‐induced agranulocytosis: 20 years of clinical observations
por: Tricta, Fernando, et al.
Publicado: (2016)

Effects of renal impairment on the pharmacokinetics of orally administered deferiprone
por: Fradette, Caroline, et al.
Publicado: (2016)

Myocardial iron overload in thalassemia major. How early to check?
por: Meloni, Antonella, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_5gi8d38kiund92ss1fn2b44nmp